Related Experiment Video
Updated: Jul 10, 2026
08:56
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Current nonsteroidal anti-inflammatory drug applications for rheumatic diseases
1Department of Medicine, New York University School of Medicine, New York.
Primary Care
|December 1, 1993
Summary
This review covers non-steroidal anti-inflammatory drugs (NSAIDs), detailing their pharmacology, safety, and mechanisms of action. Future developments, including new formulations and enantiomers, are also explored.
Area of Science:
- Pharmacology
- Drug Development
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory and analgesic properties.
- Evolving understanding of NSAID safety profiles necessitates updated knowledge for clinicians and researchers.
Purpose of the Study:
- To review current pharmacological knowledge of NSAIDs.
- To discuss changes in NSAID usage and safety perceptions.
- To explore future directions in NSAID development.
Main Methods:
- Literature review of recent pharmacological studies on NSAIDs.
- Analysis of trends in NSAID use and safety data.
- Discussion of proposed mechanisms for anti-inflammatory and analgesic effects.
- Exploration of emerging concepts like enantiomers and novel formulations.
Main Results:
- NSAIDs possess both anti-inflammatory and analgesic properties, mediated by distinct mechanisms.
- Shifting perceptions regarding NSAID safety influence clinical practice.
- Future NSAID development may involve tailored formulations and enantiomer-specific drugs.
Conclusions:
- A comprehensive understanding of NSAID pharmacology, safety, and future potential is crucial.
- Continued research into NSAID mechanisms and novel delivery systems will enhance therapeutic applications.
- Enantiomeric forms of NSAIDs may offer improved efficacy and safety profiles.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...